Suzuki D, Yamada H, Yoshida M, et al. - Researchers conducted this retrospective, single‐center, pilot study to examine the effectiveness of sodium–glucose cotransporter 2 (SGLT2) inhibitors in terms of glucose control [that is, for time‐in‐range (TIR) and glycemic variability] in Japanese individuals (n = 15) with type 1 diabetes (T1D) with low C‐peptide values. Between February 2019 and August 2019, data were analyzed from patients starting to use ipragliflozin or dapagliflozin and who used a sensor‐based flash glucose monitoring system. They calculated TIR, time above range >180 mg/dL (percentage of time with glucose level of >180 mg/dL or >10.0 mmol/L), time below range <70 mg/dL (percentage of time with glucose level of <70 mg/dL or <3.9 mmol/L), mean glucose and standard deviation, and coefficient of variation for glycemic variability, and then contrasted the results before and after SGLT2 inhibitors treatments. In Japanese patients with T1D with low C‐peptide values in real‐world practice, the treatment with SGLT2 inhibitors improved TIR, mean glucose value and SD without increasing TBR (< 70 mg/dL). SGLT2 inhibitors may help T1D patients to improve their glycemic control.